ClinicalTrials.gg
CompletedNCT00850746Updated Mar 24, 2014

A Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Adults

A Phase 1 interventional study of YM443 and Placebo in Functional Dyspepsia, sponsored by Astellas Pharma Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-03-24.

Sponsored by Astellas Pharma Inc · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing Z 338 in Dyspepsia — 1 open to participants now, 1 under way, none of them phase 3. Z 338 · Dyspepsia.

Enrollment
8th of 11
80 · median 282
Started
2009
the only one that year
Phase 1
Only one
of the 11
Registered
8th of 11
by date
Lead sponsor
3 of 11
Astellas Pharma Inc

Among the 11 studies testing Z 338 in Dyspepsia, this one is the 8th largest by enrollment, is the only one that started in 2009, is the only one in phase 1, and was the 8th registered.

Dyspepsia

372 studies on the registry are indexed under Dyspepsia; 66 are open to participants now.

Browse Dyspepsia studies →

Open to participants now

1 of the 11 studies testing Z 338 in Dyspepsia is open now. Recruiting first, the newest first:

About Z 338

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Z 338 in Dyspepsia, or all of them as a file.
02

Study summary

This study evaluates whether YM443 causes any changes in the electrocardiogram of healthy adults.

Read the detailed description

Each subject participates in all four treatment periods separated by washout periods.

In order to maintain the blind between arms, all subjects will receive the same number of tablets per day in each period of either active drug or placebo.

03

Conditions studied

  • Functional Dyspepsia

Browse trials for

Keywords

  • QT interval
  • Cardiac Repolarization
  • Cardiac Conduction
  • Healthy Subjects
  • YM443 (Z-338, acotiamide hydrochloride)
  • Evaluation of QT Interval
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Male or non pregnant, non lactating female
  • Weighing at least 45 kg
  • (BMI) between 18 and 32 kg/m2

Exclusion criteria

Exclusion Criteria:

  • The subject has evidence of any cardiac conduction abnormalities
  • The subject has a previous history of any medical or psychiatric condition that would preclude participation in the study
  • The subject has participated in another clinical trial in the last 30 days
  • The subject anticipates an inability to abstain from alcohol, or caffeine use, or from grapefruit and grapefruit juice from 48 hours prior to the administration of the first dose of YM443 on Day 1 of Period 1 and throughout the duration of the study
  • The subject has used tobacco-containing products and nicotine or nicotine-containing products within six months prior to Screening
  • The subject consumes more than 5 units of alcoholic beverages (one unit is 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits) per week or has a history of substance abuse, drug addiction, or alcoholism within 2 years prior to Screening
  • The subject has donated any whole blood or cellular blood component or has undergone significant loss of blood or has received transfusion of any blood or blood products within 56 days of Day -1 of Period 1 or has donated plasma within 7 days of Day -1 of Period 1
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Placebo comparator
    A. Placebo

    Drug: Placebo

  • Experimental
    B. Ym443 Lower Dose

    Drug: YM443

  • Experimental
    C. YM443 Higher Dose

    Drug: YM443

  • Active comparator
    D. Moxiflocxacin

    Drug: Moxifloxacin

Interventions

  • DrugYM443

    Oral

    Also known as: Z-338, acotiamide hydrochloride

  • DrugPlacebo

    Oral

  • Oral

    Also known as: Avelox

06

What researchers measure

Primary outcomes

  1. Mean change in the QTcF (Fridericia's correction) between each active treatment and placebo

    Time frame: Following four days of dosing

Secondary outcomes

  1. The mean change of the QTcI (Individual correction) and QTcB (Bazett's correction) between each active treatment and placebo.

    Time frame: Following four days of dosing

  2. The pharmacokinetics of YM443 in these subjects

    Time frame: Day 5

  3. The safety and tolerability of YM443

    Time frame: Following four days of dosing

07

Study locations

1 site
  • Tacoma, Washington 98418, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2009
First posted
Feb 25, 2009
Start
Feb 2009
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Last update
Mar 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00850746
Responsible party
Sponsor
First posted
Feb 25, 2009
Start date
Feb 2009
Primary completion
Apr 2009
Completion
Apr 2009
Last update
Mar 24, 2014

Study contacts

Use Central Contact
study director · Astellas Pharma Global Development

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Z 338

Start the discussion